Latest news with #Chlamydiatrachomatis
Daily News Egypt
27-04-2025
- Health
- Daily News Egypt
Egypt's Ministry of Health launches trachoma elimination campaign in 7 governorates
Egypt's Ministry of Health and Population has launched a campaign during April to prevent and treat the infectious eye disease trachoma (Chlamydia trachomatis) in seven governorates, according to a ministry statement. The initiative follows directives from Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population, and is part of a national plan aiming to declare Egypt free of the disease by 2027. Hossam Abdel Ghaffar, the official spokesperson for the Ministry of Health and Population, stated that the campaign reflects Egypt's commitment to improving citizens' health. He noted the campaign is part of a comprehensive national strategy implemented by the ministry in cooperation with the World Health Organization (WHO), aligning with global efforts to eliminate a major cause of preventable blindness. Trachoma is recognised as an infectious disease. Amr Kandil, Deputy Minister of Health and Population, explained that the first phase of a rapid national assessment of trachoma prevalence began in the governorates of Gharbia, Menoufia, Beni Suef, and New Valley. These four were selected based on scientific criteria to ensure the assessment comprehensively represents various living conditions and health circumstances across Egypt, covering 15 diverse health districts. Kandil added that a second phase, encompassing the governorates of Sharqia, Minya, and Qena, is underway and scheduled to conclude by the end of April. Rady Hammad, Head of the Preventive Medicine Sector, said the assessment targets the screening of more than 2,550 children aged between one and nine years, the group most vulnerable to active trachoma. He stated that specialised teams are conducting the screenings. Hammad added that examinations also include adults to identify cases of trichiasis (eyelid inversion), a serious complication of chronic trachoma infection that can lead to vision loss if not treated promptly. Regarding transmission, Hammad explained that flies play a key role by carrying contaminated secretions from eye to eye. He also cited the use of contaminated personal items, such as towels and cosmetics, belonging to infected individuals as a mode of transmission. He stressed the importance of personal and environmental hygiene – including handwashing with soap and water, avoiding touching the face, proper waste disposal, and personal care – to effectively prevent the disease and limit its spread. Amani El Habashi, Head of the Central Administration for Tropical Diseases and Disease Vectors, stated that the field assessment of prevalence is an integral part of a multi-faceted health plan. She said the plan fundamentally seeks to enhance trachoma prevention, with a particular focus on building sustained community awareness, especially in villages and remote areas potentially more susceptible to the disease's spread.
Yahoo
04-04-2025
- Health
- Yahoo
FDA approves at-home chlamydia, gonorrhea, trichomoniasis test for women
(NewsNation) — The Food and Drug Administration last week gave approval for an at-home chlamydia, gonorrhea and trichomoniasis test for women. Visby Medical Women's Sexual Health Test can be taken by those with or without symptoms,and delivers results in about 30 minutes, the FDA said in a news release. This is the first diagnostic test for chlamydia, gonorrhea and trichomoniasis that can be bought without a prescription and done entirely at home. Last year, the FDA also authorized an at-home syphilis test. 'Home tests can give people information about their health from the privacy of their home. This can be particularly important for sexual health tests for which patients may experience fear or anxiety, possibly resulting in delayed diagnosis or treatment,'Courtney Lias, Ph.D., director of the Office of In Vitro Diagnostic Devices in the FDA's Center for Devices and Radiological Health, said in a statement. 'Expanding access to tests for sexually transmitted infections is an important step toward earlier and increased diagnosis, which can result in increased treatment and reduced spread of infection.' Tariffs will drive up prices of everyday goods from coffee to toys The Visby Medical Women's Sexual Health Test, according to the FDA, correctly identified 98.8% of negative and 97.2% of positive Chlamydia trachomatis samples; 99.1% of negative and 100% of positive Neisseria gonorrhoeae samples; and 98.5% of negative and 97.8% of positive Trichomonas vaginalis samples, according to the FDA. Adam de la Zerda, the founder and CEO of Visby Medical, said the test was in development for 12 years. 'This approval is not just a milestone for Visby Medical but marks a transformative moment in medical diagnostics,' de la Zerda said in a statement. 'We've achieved something incredible; our palm-sized, single-use PCR test is simple to use and replaces a bulky, large, expensive laboratory instrument.' The test is single-use and includes a collection kit and powered testing device. Once the test is complete, results are shown on the Visby Medical App. The Visby Medical Women's Sexual Health Test is a single use, at home test, that includes a collection kit (self-collected vaginal swab) and a powered testing device, which communicates securely to the Visby Medical App, which displays results when the test is complete. More than 600,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the U.S. in 2023, the Centers for Disease Control and Prevention's Sexually Transmitted Infections (STI) Surveillance Report states. Trichomoniasis affected about 2.6 million people in 2021, per the CDC. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
31-03-2025
- Health
- Yahoo
FDA fast tracks Sanofi's mRNA vaccine for chlamydia
The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi's mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to expedite the development and review of drugs for certain medical conditions where there is currently an unmet need. Pharmaceutical companies are eligible for benefits, including more frequent meetings with the FDA and faster review times. Sanofi's vaccine is designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis, which is responsible for the most common sexually transmitted bacterial infection in the world. Treatment for the infection currently includes a regimen of antibiotics, although there are no pharmacological options to prevent the disease. Sanofi stated that health programmes initiated to prevent infection rates from rising have proven insufficient, highlighting the public health need for a vaccine. The consequences of infection in women are more serious than in men, given that pelvic inflammatory diseases can arise, a complication that can lead to infertility. Sanofi is developing the vaccine in partnership with the Queensland government, Griffith University, and the University of Queensland, all based in Australia. The vaccine has produced a 'promising pre-clinical programme', according to the drugmaker. A Phase I/II randomised clinical study, which is slated to start in the coming days, will evaluate the immunogenicity and safety of the candidate in adults aged 18 to 29 years. Sanofi has remained tight-lipped on further details of the vaccine, saying only that it is mRNA-based. Sanofi has various mRNA vaccines in development for infectious diseases, including respiratory syncytial virus (RSV), influenza, and meningitis, among others. Sanofi's global head of vaccine research and development Jean-François Toussaint said: 'Millions of people currently live with undiagnosed chlamydia, including asymptomatic infection that can also cause severe long-term health effects if left untreated. 'Antibiotics to treat chlamydia have not been successful in controlling rising infection rates. With our programme, we aim to make chlamydia a preventable disease through vaccination.' A separate vaccine candidate has already demonstrated positive results in a randomised Phase I trial (NCT03926728). Funded by the EU Horizon programme, researchers from the UK and Denmark reported in The Lancet Infectious Diseases that their candidate was safe and induced an immune response in adults. The research team have earmarked a larger Phase II trial. There are already a handful of vaccines approved to prevent certain sexually transmitted infections, including HPV and hepatitis B. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "FDA fast tracks Sanofi's mRNA vaccine for chlamydia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
26-03-2025
- Health
- Yahoo
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming days Paris, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi's mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need. The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. Following a promising pre-clinical program, Sanofi is planning a phase 1/2 randomized, clinical study designed to evaluate the immunogenicity and safety of the chlamydia vaccine candidate in adults aged 18 to 29 years. The study is due to start in coming days. Global Head of Vaccines R&D'Millions of people currently live with undiagnosed chlamydia, including asymptomatic infection that can also cause severe long-term health effects if left untreated. Antibiotics to treat chlamydia have not been successful in controlling rising infection rates. With our program we aim to make chlamydia a preventable disease through vaccination.' Chlamydia, caused by the bacterium Chlamydia trachomatis, is a common bacterial infection of the reproductive tract with consequences for developing infertility and pregnancy complications. In 2020, there were 129 million worldwide cases of chlamydia among adults (15-49 years old), with the highest rates of infection among adolescents and young adults. Although chlamydia can be treated with antibiotics when diagnosed, over 80% of chlamydia cases are asymptomatic, meaning there is a significant risk that infections go unrecognized, leading to untreated cases and unintentional transmission. Programs that have been put in place to prevent infection rates from rising have proven insufficient, highlighting the urgent public health need for a vaccine. The development of this vaccine candidate is part of the Translational Science Hub, a partnership with the Queensland Government, Griffith University, and the University of Queensland, connecting world-class researchers in Queensland, Australia, with Sanofi scientists in France and the US. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Nicolas Obrist | +33 6 77 21 27 55 | Léo Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li |+33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseSign in to access your portfolio
Yahoo
18-03-2025
- Health
- Yahoo
Man ends up in ICU after getting chlamydia from bird-feeding
TAMPA, Fla. (WFLA) — An elderly man in the Netherlands ended up suffering serious pneumonia after being infected with a bacteria strain not previously reported in humans. According to a March 2025 research letter published by 'Emerging Infectious Diseases,' the patient was a healthy 74-year-old man living in a coastal town. He lived a 'socially withdrawn lifestyle,' but he regularly fed wild aquatic birds during the winter. Anna Paulina Luna responds to 'gross' headline claiming Trump offered his bed, asked to keep it secret from Melania Part of his feeding routine included hand-feeding, and he occasionally would get bird droppings on his clothing. Researchers said the patient was admitted to a hospital in the winter of 2021 after suffering from a fever of about 102 degrees Fahrenheit, confusion, and shortness of breath for four days. The letter noted that he was a nonsmoker and was vaccinated against influenza and COVID-19. Eventually, the patient was transferred to the intensive care unit as he went into respiratory failure, requiring him to be placed on a ventilator. After a series of tests, the doctors determined that the patient had been infected with Chlamydia abortus, a strain of chlamydia that is usually known for causing fetal death in mammals. It is different from Chlamydia trachomatis, which is the strain associated with sexually transmitted infections. Researchers said the DNA of the bacteria found in the patient showed that it was an avian strain of Chlamydia abortus previously seen in migratory seabirds in the polar regions. The patient began improving upon taking doxycycline, an antibiotic, and upon a one-year follow-up, the man was fully recovered. 'In conclusion, our findings confirm the zoonotic potential of avian C. abortus to cause severe community-acquired pneumonia in humans. Increased awareness is warranted to establish the occurrence, clinical manifestations, and global geographic distribution of that rare zoonotic disease,' the letter stated. 'We recommend molecular surveillance studies in wild and captive birds to evaluate sources of contamination of different avian C. abortus genotypes.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
